Epilepsy is one of the most common neurological disorders, with a prevalence of active disease between 0.3 and 1.8% based on population-based studies across the world (0.7% in US) using medical record reviews. These studies have estimated approximately 1.4 million current epilepsy patients in the US alone. Effective seizure control often requires long-term exposure and compliance to various AEDs. Despite the advent of many new AEDs over the past 15 years, approximately 30% of epilepsy patients continue to experience recurrent seizures due to lack of treatment efficacy and discontinuation of therapy due to undesirable side effects or poor treatment compliance. Therefore, an unmet need remains for treatments that can reduce seizure frequency and severity as well as improvements in AED tolerability and safety.